|1.||Odunsi, Kunle: 31 articles (09/2015 - 09/2003)|
|2.||Gayther, Simon A: 26 articles (10/2015 - 01/2003)|
|3.||Ramus, Susan J: 23 articles (09/2015 - 01/2003)|
|4.||Webb, Penelope M: 23 articles (09/2014 - 08/2003)|
|5.||Mes-Masson, Anne-Marie: 21 articles (09/2015 - 07/2005)|
|6.||Berchuck, Andrew: 21 articles (01/2015 - 08/2004)|
|7.||Sehouli, Jalid: 20 articles (12/2015 - 03/2003)|
|8.||Cramer, Daniel W: 20 articles (06/2015 - 04/2002)|
|9.||Goodman, Marc T: 20 articles (01/2015 - 01/2003)|
|10.||Goode, Ellen L: 19 articles (09/2015 - 12/2008)|
02/01/2014 - "Complete tumor cytoreduction seems to be beneficial for patients with recurrent epithelial ovarian cancer (REOC). "
10/01/2005 - "Our data suggest that peri-tumoral mast cell infiltration in tumors with high MVD predicts for improved survival in women with advanced epithelial ovarian cancer."
04/01/2003 - "Expression of survivin gene was detected in a significantly greater proportion in epithelial ovarian cancer and borderline tumors than benign tumors and normal tissue. "
03/01/2014 - "Although clinical data with antiangiogenics are groundbreaking in several tumors such as ovarian epithelial cancer, overall efficacy of these agents is far from what was initially envisaged. "
01/01/2012 - "Targeted therapies have been used to combat many tumor types; however, few have effectively improved the overall survival in women with epithelial ovarian cancer, begging for a better understanding of this deadly disease and identification of essential drivers of tumorigenesis that can be targeted effectively. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
10/15/2015 - "Epithelial ovarian cancer (EOC) is still considered the most lethal gynecological malignancy and improved early detection of ovarian cancer is crucial to improving patient prognoses. "
04/15/2007 - "These studies show that alterations in the angiogenic characteristics of ovarian surface epithelium may play an important role in the etiology of ovarian cancer, and that inhibition of angiogenesis can be effective in the treatment of epithelial ovarian cancer."
11/01/2014 - "Multiple mouse models with C200 and A2780 epithelial ovarian cancer cell lines were used to assess the efficacy of Minnelide in inhibiting ovarian cancer growth. "
09/10/2015 - "The aim of this study was to estimate the contribution of deleterious mutations in the RAD51B, RAD51C, and RAD51D genes to invasive epithelial ovarian cancer (EOC) in the population and in a screening trial of individuals at high risk of ovarian cancer. "
03/01/2014 - "The Australian Ovarian Cancer Study (AOCS) is a prospective population-based study of women newly diagnosed with primary epithelial ovarian cancer. "
10/01/2014 - "This study investigated the expressions of AGTR1 and AGTR2 in epithelial ovarian carcinoma and the therapeutic potential of AGTR modulation with specific antagonist and/or agonist in epithelial ovarian cancer cells. "
05/01/2014 - "In this study, we evaluated the expression of REV7 in epithelial ovarian cancer (EOC) and analyzed the association between its expression and chemosensitivity in ovarian clear cell carcinoma (CCC) cells. "
04/01/2013 - "The aim of this study was to compare clinicopathologic characteristics, surgery outcomes and survival outcomes of patients with stage III and IV mucinous epithelial ovarian cancer (mEOC) and serous epithelial ovarian carcinoma (sEOC). "
01/01/2011 - "The study attempted to evaluate the kinetics of changes in serum TRAIL levels as a potential predictive and prognostic factor in patients with epithelial ovarian cancer (EOC) or primary peritoneal carcinoma (PPC), eligible for an interval debulking surgery (IDS). "
11/01/2009 - "A series of patients (N=26) diagnosed with peritoneal carcinomatosis for recurrent epithelial ovarian cancer (stage III) from January 1997 to December 2004 submitted to radical surgery/peritonectomy with optimal cytoreduction (R0-R1) were included in this study, 14 treated with HIPEC and 12 without HIPEC. "
|4.||Neoplasm Metastasis (Metastasis)
10/01/1995 - "Most patients with this disease usually have good prognoses, but with metastasis or recurrence, no therapy is as effective as in epithelial ovarian cancer. "
10/01/2015 - "The aim of the present study was to determine the impact on survival of parenchymatous versus peritoneal splenic metastases versus splenic hilum lymph node involvement at the time of primary cytoreduction for advanced-stage epithelial ovarian cancer. "
01/01/2015 - "The purpose of this study was to investigate the effect of down-regulated HOTAIR expression on tumorgeniesis and metastasis of epithelial ovarian cancer (EOC) CSCs. "
12/01/2014 - "Thus, this study suggested that the epithelial ovarian cancer invasion and metastasis can be inhibited by antagonizing CCR7. "
02/01/2014 - "In this study, we investigated whether the levels of total HSP27 were detectable in serum and whether it could be a predictive biomarker for peritoneal metastases in epithelial ovarian cancer. "
09/01/2003 - "In this study, we have demonstrated that ascites-derived epithelial ovarian cancer cells lack membranal FasL but constitutively secrete whole, intracellular FasL (37 kDa) via the release of microvesicles. "
12/01/2015 - "Malignant ascites (MA) is most commonly observed in patients scheduled for epithelial ovarian cancer (EOC) surgery and is supposed as a major risk factor promoting perioperative hemodynamic deterioration. "
12/01/2015 - "Hemodynamic Consequences of Malignant Ascites in Epithelial Ovarian Cancer Surgery*: A Prospective Substudy of a Randomized Controlled Trial."
11/15/2015 - "Malignant ascites is a common complication in the late stages of epithelial ovarian cancer (EOC) that greatly diminishes the quality of life of patients. "
11/15/2015 - "Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer."
|7.||Biological Markers (Surrogate Marker)
|8.||DNA (Deoxyribonucleic Acid)
|9.||Progesterone Receptors (Progesterone Receptor)
|10.||Adenosine Triphosphate (ATP)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)